Literature DB >> 23239493

Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension.

M Patricia George1, Hunter C Champion, Marc Simon, Siobhan Guyach, Rebecca Tarantelli, Heather M Kling, Alexandra Brower, Christopher Janssen, Jessica Murphy, Jonathan P Carney, Alison Morris, Mark T Gladwin, Karen A Norris.   

Abstract

Pulmonary arterial hypertension (PAH) is increased in HIV, but its pathogenesis is not fully understood. Nonhuman primates infected with simian immunodeficiency virus (SIV) or SIV-HIV chimeric virus (SHIV) exhibit histologic changes characteristic of human PAH, but whether hemodynamic changes accompany this pathology is unknown. Repeated measurements of pulmonary artery pressures would permit longitudinal assessments of disease development and provide insights into pathogenesis. We tested the hypothesis that SIV-infected and SHIV-infected macaques develop physiologic manifestations of PAH. We performed right heart catheterizations, echocardiography, and computed tomography (CT) scans in macaques infected with either SIV (ΔB670) or SHIV (89.6P), and compared right heart and pulmonary artery pressures, as well as pulmonary vascular changes on CT scans, with those in uninfected control animals. Right atrial, right ventricular systolic, and pulmonary artery pressures (PAPs) were significantly elevated in 100% of macaques infected with either SIV or SHIV compared with control animals, with no difference in pulmonary capillary wedge pressure. PAPs increased as early as 3 months after SIV infection. Radiographic evidence of pulmonary vascular pruning was also found. Both SIV-infected and SHIV-infected macaques exhibited histologic changes in pulmonary arteries, predominantly consisting of intimal and medial hyperplasia. This report is the first to demonstrate SHIV-infected and SIV-infected macaques develop pulmonary hypertension at a high frequency, with physiologic changes occurring as early as 3 months after infection. These studies establish an important nonhuman primate model of HIV-associated PAH that will be useful in studies of disease pathogenesis and the efficacy of interventions.

Entities:  

Mesh:

Year:  2012        PMID: 23239493      PMCID: PMC3604086          DOI: 10.1165/rcmb.2011-0434OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  43 in total

Review 1.  Primate models of AIDS.

Authors:  S V Joag
Journal:  Microbes Infect       Date:  2000-02       Impact factor: 2.700

2.  Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era.

Authors:  Alison Morris; Matthew R Gingo; M Patricia George; Lorrie Lucht; Cathy Kessinger; Vikas Singh; Maria Hillenbrand; Michelle Busch; Deborah McMahon; Karen A Norris; Hunter C Champion; Mark T Gladwin; Yingze Zhang; Chad Steele; Frank C Sciurba
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

3.  Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension.

Authors:  Amie K Lund; Joann Lucero; Lindsay Herbert; Yushi Liu; Jay S Naik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-06-17       Impact factor: 5.464

4.  Pulmonary vascular lesions are common in SIV- and SHIV-env-infected macaques.

Authors:  M Patricia George; Alexandra Brower; Heather Kling; Tim Shipley; Jan Kristoff; Todd A Reinhart; Michael Murphey-Corb; Mark T Gladwin; Hunter C Champion; Alison Morris; Karen A Norris
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

5.  Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction.

Authors:  Navneet K Dhillon; Fang Li; Bing Xue; Ossama Tawfik; Susan Morgello; Shilpa Buch; Amy O'Brien Ladner
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-27       Impact factor: 6.914

6.  Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.

Authors:  Hilario Nunes; Marc Humbert; Olivier Sitbon; Jane H Morse; Zemin Deng; James A Knowles; Catherine Le Gall; Florence Parent; Gilles Garcia; Philippe Hervé; Robyn J Barst; Gérald Simonneau
Journal:  Am J Respir Crit Care Med       Date:  2003-02-25       Impact factor: 21.405

7.  Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension.

Authors:  H A Ghofrani; G Friese; T Discher; H Olschewski; R T Schermuly; N Weissmann; W Seeger; F Grimminger; J Lohmeyer
Journal:  Eur Respir J       Date:  2004-02       Impact factor: 16.671

8.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

9.  Clinical and therapeutical follow-up of HIV-associated pulmonary hypertension: prospective study of 10 patients.

Authors:  Franco Recusani; Angela Di Matteo; Fabiana Gambarin; Andrea D'Armini; Catherine Klersy; Carlo Campana
Journal:  AIDS       Date:  2003-04       Impact factor: 4.177

10.  Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling.

Authors:  Joel Mermis; Haihua Gu; Bing Xue; Fang Li; Ossama Tawfik; Shilpa Buch; Sonja Bartolome; Amy O'Brien-Ladner; Navneet K Dhillon
Journal:  Respir Res       Date:  2011-08-05
View more
  26 in total

Review 1.  Age-Associated Pathology in Rhesus Macaques (Macaca mulatta).

Authors:  H A Simmons
Journal:  Vet Pathol       Date:  2016-02-10       Impact factor: 2.221

2.  Prevalence and hospital discharge status of human immunodeficiency virus-associated pulmonary arterial hypertension in the United States.

Authors:  Marshaleen Henriques-Forsythe; Srinadh Annangi; Harrison W Farber
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 3.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

Review 4.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

Review 5.  Infections in the immunosuppressed host.

Authors:  M Patricia George; Henry Masur; Karen A Norris; Scott M Palmer; Cornelius J Clancy; John F McDyer
Journal:  Ann Am Thorac Soc       Date:  2014-08

Review 6.  Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Authors:  Sébastien Bonnet; Steeve Provencher; Christophe Guignabert; Frédéric Perros; Olivier Boucherat; Ralph Theo Schermuly; Paul M Hassoun; Marlene Rabinovitch; Mark R Nicolls; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

Review 7.  Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Stephen Y Chan; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-24       Impact factor: 4.733

8.  CCR5 as a treatment target in pulmonary arterial hypertension.

Authors:  Larissa Lipskaia; Shariq Abid; Lucie Poupel; Valérie Amsellem; Amal Houssaini; Rozenn Quarck; Elisabeth Marcos; Nathalie Mouraret; Aurélien Parpaleix; Régis Bobe; Guillaume Gary-Bobo; Mirna Saker; Jean-Luc Dubois-Randé; Mark T Gladwin; Karen A Norris; Marion Delcroix; Christophe Combadière; Serge Adnot
Journal:  Circulation       Date:  2014-07-03       Impact factor: 29.690

9.  How does inflammation contribute to pulmonary hypertension?

Authors:  Rahul Kumar; Brian Graham
Journal:  Eur Respir J       Date:  2018-01-25       Impact factor: 16.671

Review 10.  Human immunodeficiency virus-associated pulmonary arterial hypertension.

Authors:  Christopher F Barnett; Priscilla Y Hsue
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.